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Abstract
Background: To evaluate the role of computed tomography (CT) and positron
emission tomography (PET)/CT in patients with thymic cancer and thymoma at
initial staging.
Methods: We retrospectively reviewed CT and PET/CT scans of 26 patients with a
thymic cancer (n = 9) or thymoma (n = 17). Chest CT findings documented were
qualitative and quantitative. Both qualitative and semiquantitative data were recov-
ered by PET/CT. The comparisons among histological entities, outcome, and quali-
tative data from CT and PET/CT were made by non-parametric analysis.
Results: PET/CT resulted positive in 15/17 patients with thymoma. CT was avail-
able in 5/9 (56%) patients with thymic cancer and in 3/17 with thymoma.All quan-
titative CT parameters were significantly higher in patients with thymic cancer than
thymoma (maximum axial diameter: 45 vs. 20 mm, maximum longitudinal diam-
eter: 69 vs. 21 mm and volume: 77.91 vs. 4.52 mL; all P < 0.05). Conversely, only
metabolic tumor volume (MTV) and total lesion glycolysis were significantly differ-
ent in patients with thymic cancer than thymoma (126.53 vs. 6.03 cm3 and 246.05
vs. 20.32, respectively; both P < 0.05). After a median follow-up time of 17.45
months, four recurrences of disease occurred: three in patients with thymic cancer
and one with a type B2 thymoma. CT volume in patients with recurrent disease was
102.19 mL versus a median value of 62.5 mL in six disease-free patients. MTV was
higher in the recurrent than disease-free patient subset (143.3 vs. 81.13 cm3),
although not statistically significant (P = 0.075).
Conclusion: Our preliminary results demonstrated that both morphological and
metabolic volume could be useful from a diagnostic and prognostic point of view in
thymic cancer and thymoma patients. A large multi-center clinical trial experience
for confirming the findings of this study seemsmandatory.
Introduction
Thymoma is a rare tumor accounting for <1% of all adult
malignancies, although it is the most common primary neo-
plasm of the anterior mediastinum. Thymoma is the most
common thymic epithelial neoplasm; however, thymic carci-
noma and thymic carcinoid are also recognized. Because
thymoma is a rare disease, an international collaboration and
a dedicated work group have been created, the International
Thymic Malignancy Interest Group (ITMIG). To facilitate
collaborative research efforts and formation of a uniform
thymoma database, ITMIG has adopted the Masaoka-Koga
staging system as the official staging system for thymoma.
This system is based on gross operative findings with micro-
scopic confirmation of invasive tumor properties. Con-
versely, theWorldHealth Organization (WHO) classification
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distinguishes thymic lesions according to their histological
pattern. Both the WHO histologic classification of thymic
epithelial tumor1,2 and the clinic-pathologic staging system
proposed by Masaoka et al.3 have been reported to reflect the
oncological behavior of thymoma and, hence, the prognosis.
Imaging plays a role in thymoma identification, extension,
global staging, restaging, and evaluation of response to treat-
ment. Initial investigation of thymoma starts with a chest
radiograph followed by chest-computed tomography (CT)
and is rarely completed by magnetic resonance imaging
(MRI) or nuclearmedicine studies (such as 111In-octreoscan
scintigraphy or positron emission tomography [PET] with
18F-Fluorodeoxyglucose [FDG]).
The purposes of the present study were: (i) to evaluate the
role of CT and FDG PET/CT in thymic lesions in initial
staging, (ii) to correlate imaging findings with the prognosis
of thymic lesions, and (iii) to compare our findings with
current literature.
Materials and methods
Patient population
From April 2008 to December 2012, we retrospectively
reviewed a total of 90 FDG PET/CT scans that were per-
formed on 56 patients with a known or suspected thymic
disease. Moreover, in 32 subjects of the same population, we
collected 38 CT scans performed within three months of the
PET/CT studies.Thirty-five PET/CT scanswere performed at
initial staging, 28 for restaging, 17 for evaluation of response
to therapy, and 10 for long term follow-up. Out of 38 CT
scans, 14 were made at initial staging, eight for restaging, six
for response to therapy, and 10 for follow-up. For the end
points of the present study,we considered 26patients at initial
staging of thymoma or thymic cancer. There were eight male
and 18 female patients (30.8 vs. 68.2%, respectively). The
median age was 57.5 years (31–78 years). All patients had a
PET/CT scan,while only eight subjects had an available CT in
the same setting. The defined diagnosis was obtained by sur-
gical specimens after thymectomy. The surgical specimens
were reviewed by two experienced pathologists, and the
tumors were divided into six subtypes on the basis of WHO
classification: type A, type AB, type B1, type B2, type B3, and
thymic carcinoma.All of the tumors were staged on the basis
of the presence and extent of transcapsular invasion into
adjacent mediastinal tissues as determined by surgical find-
ings and confirmed by microscopic examination:3 stage I,
encapsulated tumor without microscopic evidence of capsu-
lar invasion; stage II,microscopic or macroscopic invasion of
the surrounding fatty tissue or the mediastinal pleura; stage
III, macroscopic invasion of neighboring organs, such as the
pericardium, lung or the great vessels; and stage IV, pericar-
dial or pleural dissemination (IVa) and lymphnode or distant
metastases (IVb). This study was approved by the local insti-
tutional review board for retrospective analysis, and was con-
ducted according to the Declaration of Helsinki (2000).
Computed tomography (CT) imaging
All chest CT examinationswere acquired from the lung apices
through the middle portions of both kidneys. Three exami-
nations were made using a 40-row detector CT (Somatom
Definition AS; Siemens Medical Systems, Erlangen,
Germany) using the following parameters: section thickness
3 mm, reconstruction 2 mm, gantry rotation time 0.5
seconds, pitch 0.8, tube potential 120 kV, and mAs setting
adjusted for body weight. All patients received intravenous
contrast medium (2 mL/kg; flow rate 3 mL/second;
Omnipaque 350; GE Healthcare, Milan, Italy). Imaging data
of hard copies in five patients whose CT scans were obtained
at other hospitals were scanned and uploaded to a picture
archiving and communication system. All monitors showed
images obtained using both mediastinal (width, 400 H; level,
20 H) and lung (width 1.500 H, level −700 H) window set-
tings. Multiplanar reconstruction images were assessed for
lesion shape and size. CT images were reviewed and inter-
preted by two radiologists with at least five years experience of
chest CT interpretation. Both specialists were presented with
the patients’ clinical history, but were unaware of histological
findings. Chest CT scans were also retrieved to a commer-
cially available stand-alone workstation loaded with com-
mercial volume CT software (syngo.via, Siemens, Hoffman
Estates, IL, USA) which automatically measured the tumor
volume by calculating the space that is enclosed within the
segmented tumor. Qualitative and quantitative chest CT
findings were documented for each patient; in particular, the
tumor shape was classified as round if the long-to-short axis
ratio was less than or equal to 1.5, oval if the ratio was greater
than 1.5 but less than 3.0, and plaque-shaped if the ratio was
greater than 3.0.Marginal characteristicswere subclassified as
smooth, lobulated or irregular. Tumor necrosis and calcifica-
tions were considered. The pattern of enhancement was
recorded as homogeneous or heterogeneous and the degree
of enhancement was classified as low or high compared to
that of the chest wall muscle. Fatty mediastinal infiltration,
great vessel invasion (such as the degree of abutment), pleural
and pericardial effusion, and enlarged lymph nodes were
evaluated. Among quantitative variables, tumor size (two
maximal axial diameters and maximal longitudinal diameter
measured bymulti planar reconstruction (MPR) and volume
(in mL) were computed.
Positron emission tomography
(PET)/CT protocol
Whole body FDG PET/CT was performed using a dedicated
PET/CT scanner (Biograph 16 HT, Siemens Medical Solu-
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tions, Hoffman Estates, IL, USA). The PET component is a
high-resolution scanner with a spatial resolution of 4.7 mm
and has no septa, thus allowing only 3-dimensional (3D)
acquisitions. The CT portion of the scanner is the Somatom
Sensation 16-slice CT. Together with the PET system, the CT
scanner is used both for attenuation correction of PET data
and for localization of FDG-uptake in PET images. All
patients were advised to fast for at least six hours before the
integrated PET/CT examination. After injection of 3.0 MBq
of FDG per kg/bw, patients rested for a period of approxi-
mately 60 minutes in a comfortable chair. A low dose CT
was performed for the attenuation correction. Emission
images ranging from the proximal femur and the base of the
skull were acquired for three minutes per bed position.
Acquired images were reconstructed using the attenuation
weighted-ordered subset expectation maximization iterative
reconstruction, with two iterations and eight subsets.
Fourier rebinning was used to reduce the 3D dataset to a 2D
equivalent dataset, and a 4-mm full width at half maximum
Gaussian filter was applied to the image after reconstruction
along the axial and transaxial directions. The data were
reconstructed over a 128 × 128 matrix with 2 mm pixel size
and slice thickness. Processed images were displayed in
coronal, transverse, and sagittal planes. Two experienced
nuclear medicine physicians interpreted the PET/CT
images, unaware of previous findings. At visual analysis,
increased FDG uptakes not corresponding to physiological
uptake patterns or in any foci of increased uptake corre-
sponding to a CT abnormality were recorded as positive.
The absence of an uptake was used to define a negative
PET/CT finding.
The metabolic tumor volume (MTV), maximum,
minimum, and average standardized uptake value (SUVmax,
SUVmin and SUVavg, respectively) were determined by
drawing iso-volumetric regions of interest (VOI) on the
attenuation corrected PET/CT images around suspected
thymic lesions. Moreover, the SUVmax of the aortic arch
was taken as a reference region for background mediastinal
activity (or blood-pool activity). Therefore, the tumor/
mediastinum ratio was calculated by the ratio of thymic
lesion SUVmax (T) and blood pool SUVmax (M).Finally, the
total lesion glycolysis (TLG) of thymic lesions was computed
according to the formula: TLG = MTVxSUVavg.
Follow-up
Data was collected via scripted telephone interviews by a
researcher blinded to the patient’s test result and then con-
firmed by the revision of medical archives or by contacting
the patient’s general practitioner. To determine follow-up
time, the date of the last examination or consultation was
used. Defined events included local or distant recurrence
confirmed by biopsy or conventional imaging modalities.
Literature research strategy
A computer literature analysis on studies in human subjects
was performed to identify articles that evaluated the role of
PET or PET/CT, CT, andMRI in thymic disease.
Pubmed and Web of Knowledge were used to compile
data from 2004 to January 2014, with the following key
words: “THYMOMA or Thymic carcinoma” AND” CT”
AND “MRI”, “THYMOMA” AND “CT” NOT “PET” and
“THYMOMAAND PET.”
Reviews, clinical reports, and editor comments were
excluded. Moreover, articles that did not evaluate the role of
CT or MRI or FDG PET or PET/CT in adult thymic lesions
were also excluded.We found 91 articles for thymoma andCT
and MRI without any filters; when we added HUMANS/
JOURNALS ARTICLE/ENGLISH LANGUAGE as filters, a
total of 24 articles were obtained. Considering the words
thymoma AND CT NOT PET, 419 articles were found, for a
total of 91 after filters. Of all of the research compiled, eight
articles on thymoma and radiologic examinations for initial
assessmentwere recovered. Similarly, 77 reports evaluated the
role of FDG PET or PET/CT in thymic disease, but only 12
met the inclusion criteria.
Statistical analysis
A non-parametric statistical analysis was used, such as the
chi-square, U-Mann Whitney or Wilcoxon test, as appropri-
ate. A P-value <0.05 was defined as significant. Survival
curves were constructed using the Kaplan-Meier method to
account for censored survival times and were compared with
the log rank test. Progression-free survival was defined as the
length of time from the date of PET/CT to any relapse (local
or distance recurrence). Statistical analysis was performed
with SPSS software (SPSS Inc. Chicago, IL, USA).
Results
Clinical and histopathological data
Table 1 reports the clinical and histopathological characteris-
tics of the study population.Seventeen (65.4%)patients had a
histologically proven thymoma, while nine (34.6%) had a
thymic cancer. WHO classification was type A/B in three
(11.5%) patients, type B1 in three (11.5%), type B1/B2 in one
(3.8%), type B2 in three (11.5%), and type B3 in seven
(26.9%) patients. The Masaoka-Koga system was stage I in
three (11.5%) patients, stage IIa in six (23%), stage IIb in one
(3.8%), stage III in six (23%), stage IVa in four (15.7%), and
stage IVb in six (23%) patients. Among nine patients with
thymic cancer, one (11.1%) was stage IIB, two (22.2%) were
stage III, two (22.2%) were stage IVA, and four (44.5%) were
stage IVB.
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PET/CT and CT findings
Of the 17 patients with thymoma, 15 (88.2%) showed a posi-
tive PET/CT scan, whereas two had a false-negative finding.
On the other hand,100%of patientswith thymic cancer had a
positive scan. CT was available in 5/9 (56%) patients with
thymic cancer and in 3/17 (17.6%) with thymoma. In all
cases, CT clearly identified the primary tumor.
Tumor necrosis, calcifications, fat infiltration, and pleural
effusion were more frequent in thymic cancer compared to
thymoma. Conversely, infiltration of vessels was reported
both in thymic cancer and in thymoma, as illustrated in
Table 2. All quantitative CT parameters were significantly
higher in patients with thymic cancer than thymoma
(median maximum axial diameter: 45 vs. 20 mm, median
maximum longitudinal diameter: 69 vs. 21 mm, and median
volume: 77.91 vs. 4.52 mL; all P < 0.05). Conversely, among
semiquantitative PET/CT features, only MTV and TLG were
significantly different in patients with thymic cancer than
thymoma (Table 3), while SUVmax, SUVavg, and T/B ratio
was similar, although with a trend to increase in thymic
cancer. Figure 1 illustrates two examples of CT and PET/CT
images in patients with thymic and thymoma cancer, respec-
tively. According to Masaoka clinical staging, 10 (38.5%)
patients were at stage I-II and 16 (61.5%) were at stage III-IV.
Table 4 demonstrates that maximum longitudinal diameter,
Table 1 Characteristics of study population
Characteristics
Median age (range), years 57.5 (31–78)
Histological subtype, n (%)
Thymoma AB 3 (11.5%)
Thymoma B1 3 (11.5%)
Thymoma B1/B2 1 (3.8%)
Thymoma B2 3 (11.5%)
Thymoma B3 7 (26.9%)
Thymic cancer 9 (34.6%)
Stage, n (%)
I 3 (11.5%)
II 7 (26.9%)
III 6 (23.1%)
IVA 14 (15.4%)
IVB 6 (23.1%)
Gender, n (%)
Male 8 (30.8%)
Female 18 (69.2%)
Median volume (range)
CT (morphological), mL 62.5 (3.30–306.9)
PET/CT (metabolic), cm3 83.5 (0.06–690)
Following treatments, n (%)
Surgery† 26 (100%)
Systemic treatment‡ 13 (50%)
Radiotherapy 5 (19.2%)
†Radical and non-radical. ‡Neoadjuvant or adjuvant chemotherapy. CT,
computed tomography; PET, positron emission tomography.
Table 2 Computed tomography characteristics
Thymic cancer (n = 5) Thymoma (n = 3) P-value
Necrosis 2 (60%) 0 0.673*
Calcifications 2 (40%) 0 0.673*
Fat infiltration 4 (80%) 0 0.144*
Infiltration of vessels 3 (60%) 3 (100%) 0.673*
Pleural effusion 2 (40%) 0 0.673*
Median maximum axial
diameter (in mm)
45 (28–80) 20 (15–27) 0.025**
Median maximum
longitudinal diameter (in
mm)
69 (24–109) 21 (3–22) 0.025**
Median volume (in mL) 77.91 (10.5–251) 4.52 (3.30–7.10) 0.025**
*Chi-square test corrected for Yates. **U-Mann Whitney.
Table 3 PET/CT characteristics
Thymic cancer (n = 9) Thymoma (n = 17) P-value*
SUVmax 9.34 (3.2–23.5) 4.84 (1.5–25.9) 0.100
SUVavg 4.75 (2.98–8.28) 3.39 (0.78–8.85) 0.247
T/B ratio 3.07 (1.67–3.79) 2.06 (0.63–5.05) 0.112
MTV 126.53 (0.4–690.02) 6.03 (0.06–240.21) 0.043
TLG 642.05 (1.10–3374.20) 20.32 (0.05–1570.97) 0.056
*U-Mann-Whitney test. CT, computed tomography; MTV, metabolic tumor volume; PET, positron emission tomography; SUV avg, standardized uptake
value average; SUVmax, SUVmaximum; T/B tumor/background; TLG, total lesion glycolysis.
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volume atCT,MTV,andTLGat PETwere significantly higher
in patients at stage III-IV than those at stage I-II.
Analysis of literature research
From the collection of published papers on FDG PET/CT, it
emerged that four studies have compared mean SUVmax
among low and high-risk thymoma, and thymic cancer
patients.4–7 The median SUVmax in 175 patients were 4.48,
6.75, and 10.80 for low and high-risk thymoma, and thymic
cancer, respectively. As shown in Figure 2a, a slight overlap
was found between the three categories. Conversely, the
median SUVmax of thymoma and thymic cancer, obtained
from 95 patients enrolled in another four studies,8–11 were
3.37 and8.68, showing a large gap (Fig 2b).Moreover, consid-
ering studies that evaluated the relationship between CT
measures and thymic disease, we found that in non-invasive
thymoma, morphological characteristics were substantially
similar to the results of Priola et al.12 and Tomiyama et al.13 In
particular, smooth contour,homogeneous enhancement, and
partial mediastinal fat infiltration were detected in >50% of
patients. Conversely, only the presence of lobulated contours
was equally distributed in both patient populations,while the
residual CT data (such as necrotic or cystic component and
calcifications) were different. Studies by Sadohara et al.,14
Jeong et al.,15 and Liu et al.16 focused on the differentiation
among low and high-risk thymoma, and thymic cancer.
According to their results, a similar distributionwas found for
homogeneous contours in low-risk thymoma, for lobulated
contours in high-risk thymoma, and for the presence of
necrotic or cystic components and heterogeneous enhance-
ment in thymic cancer.
Figure 1 Positron emission tomography/computed tomography (CT) and CT images of (a,b) a thymoma, and (c,d) thymic cancer.
Table 4 Masaoka clinical staging and semiquantitative imaging findings
CT PET/CT
MLD Volume MTV TLG
Stage I-II 21.5 (3–69) 5.81 (3.30–54.78) 0.34 (0.06–118.91) 1.15 (0.05–912.04)
Stage III-IV 73 (24–109) 77.9 (10.5–306.9) 95.08 (0.34–690.02) 466.45 (1.01–3374.20)
P-value 0.026 0.013 0.003 0.003
CT, computed tomography; MLD, ***; MTV, metabolic tumor volume; PET, positron emission tomography; TLG,total lesion glycolysis.
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Outcome
After a median follow-up of 17.45 months (range: 1–50
months), four patients experienced a recurrence of disease:
three in patients with thymic cancer and one with a type B2
thymoma. Follow-up data were lost in three subjects. The
medianCT volume in two patients with recurrent disease was
102.19 mL versus 62.50 mL in six disease-free patients (P =
0.865). MTV and TLG were higher in the recurrent than in
the disease-free patient subset (143.3 vs. 81.13 and 756.8 cm3
vs. 322.31, respectively); however, these results were not sta-
tistically significant (P = 0.075 and 0.118). In Kaplan-Meier
analysis, a MTV and a TLG higher than 83.5 cm3 and 371.3,
respectively, was associated with a poor prognosis (Fig 3).
Discussion
In the present study,we retrospectively analyzed themorpho-
logical and metabolic measurements of a patient series with
thymoma and thymic cancer usingCT andPET/CT examina-
tions at initial staging of disease. The main purpose of our
study was to define the role of CT and PET/CT in patients
with thymoma and thymic cancer, in order to help clinicians
and surgeons in the management of these diseases, consider-
ing the strong support of histological data. Nowadays, both
CT and PET/CT are employed in patients with thymic cancer,
particularly for defining the extension of disease and for
determining the clinical stage. We would like to underline
that PET/CT and CT can be interpreted both by visual analy-
Figure 2 Box-plots of semiquantitative positron emission tomography/computed tomography data obtained from literature research.
Figure 3 Progression-free survival curves in accordance with metabolic positron emission tomography measures.
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sis and by a semiquantitative/quantitative point of view.
These latter criteria could be useful in clinical practice to dis-
tinguish between low and high disease staging and between
poor and good prognoses.
Table 5 reports the list of studies in the literature
research.4–23 The majority of reports concerning FDG PET or
PET/CT focused on the differences between semiquan-
titative data and histological patterns.4,6–9,14–17,19,22,23 In par-
ticular, Igai et al.,8 Sung et al.,7 Benveniste et al.,4 Fukumoto
et al.,6 and Lococo et al.17 concluded that there was a signifi-
cant difference in SUVmax between the thymoma and
thymic carcinoma groups, indicating that this parameter
may be useful for discriminating thymoma from thymic car-
cinoma. In an analysis of 95 patients, SUVmax differentiated
patients with thymoma from thymic cancer (see Fig 2b). It is
probable that the inclusion of low-risk thymoma patients in
the analysis of semiquantitative PET data could lead to lower
SUVmax results than if the study only included high-risk
thymoma and thymic cancer patients (see Fig 2a). Con-
versely, in the present study we observed an increasing ten-
dency of SUVmax and tumor/background (T/B) ratio
according to thymoma and thymic carcinoma, although this
was not statistically significant. On the other hand, MTV
shows a significantly different value in thymoma patients
when compared to thymic cancer patients (6.03 vs.
126.53 cm3; P = 0.043). Therefore, this latter parameter
could be more appropriate than SUVmax for the differential
diagnosis between malignant and potentially malignant
thymic lesions.
Table 5 summarizes the findings of eight studies focusing
on the role of CT in thymoma and thymic cancer.12–16,18,20,21 All
studies reported quantitative data, essentially tumor size
measured asmaximum trans-axial diameters, and qualitative
data (i.e. shape, contour, density, pattern of enhancement,
infiltration of fat surrounding tumor and great vessel inva-
sion, pleural and pericardial effusion, and lymph node
involvement). Only Maroom et al. reported data including
tumor volume; however, no definitive finding was clearly dis-
cussed.20 Analysis of the collected CT data revealed that
homogeneous contours are typical of non-invasive and low-
risk thymoma, while lobulated contour and heterogeneous
enhancement are linked with high-risk thymoma or thymic
cancer. In our study, we found that tumor volume can differ-
entiate thymoma from thymic cancer and distinguish
patients at stage I-II from those at stage III-IV. In accordance
with Maroom et al.,20 we considered MPR, whereas the
majority of studies based their measurement on axial plane
alone.
The advantage of using both anatomical and metabolic
volumes would be evident in a more accurate evaluation of
disease extension. In fact, stage I is classified as completely
encapsulated tumor, stage II as microscopic transcapsular
invasion (IIa) or macroscopic invasion into thymic or sur-
rounding fatty tissue (IIb), stage III as macroscopic invasion
into neighboring organ (i.e. pericardium, great vessel or
lung), and stage IV as pericardial or pleural metastases (IVa)
or lymphogeneous or hematogenous metastases (IVb).
Therefore, stage I and IIa tumors are confined in the thymic
capsule while stage IIb –III and IV are characterized by an
infiltrative form that can be associated with a longitudinal
extension, rather than posterior-anterior growth. Therefore,
CT image measurement based on three perpendicular diam-
eters should be used for the evaluation of thymic lesions.
Similarly, metabolic volume by PET could prompt more
clinical data.
None of the studies listed in Table 5 evaluated the prognos-
tic role of CTor PET/CT in thymic neoplasms.As reported by
Lococo et al.,17 while there is a body of evidence suggesting
that PET SUVmax could reflect the rate of proliferation and
degree of invasiveness of thymic neoplasms – thus providing
a useful index for diagnosis and treatment – its prognostic
role is still debated and remains controversial. Following the
lines of extreme simplification wemay suppose with a logical
assertion that SUVmax and SUVmax/T index may indeed
have a prognostic value in thymic neoplasms, directly associ-
ated to the different risk classes; however, to date there is no
evidence or robust data supporting this assumption. In our
study we found that high MTV and TLG (>83.5 cm3 and
371.3, respectively) were associated with a poorer prognosis
in this setting of patients. A low rate of recurrence (n = 4/26;
15.4%) was reported in the present study. Although no
unique prognostic factor has been identified, several studies
have indicated the importance of clinical features (i.e. age and
the presence or absence of myasthenia gravis), Masaoka
staging, the completeness of surgical resection, WHO histo-
logic type, size of tumor, and great vessel or mediastinal inva-
sion as predictors of recurrence and survival after surgical
resection. Patients in stage I and II with a high-risk thymoma
have a significantly poorer prognosis (higher recurrence rate
and reduced survival) than those with a low-risk thymoma.24
Based on this data, we found that MLD, volume at CT, MTV
and TLG at PET were significantly higher in patients at stage
III-IV than those at stage I-II and, therefore, directly corre-
lated with prognosis. In addition, we found that after 18
months of follow-up in two patients with disease recurrence,
the volume of the tumor in CT images was larger than in
patients free of disease.
All selected patients were treated by surgical resection, in
some cases associated with chemotherapy (n = 13; as
neoadjuvant or adjuvant) and/or adjuvant radiotherapy (n =
5). Although the association between prognosis and thera-
peutic regimen is beyond the aim of the present study, we
indirectly found that combined therapeutic modalities have
an important impact on the event-free survival rate. In fact, in
our patient population, only four recurrences occurred after
18 months of follow-up.
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The present study has some limitations: (i) different types
of CT scanner were used, including hard copies of scans in
five patients; (ii) a small number of patients were included
and a retrospective designwas used; and (iii) a short period of
follow-up could be correlated with a lower number of events.
Particularly, the fact of the small sample size cannot, there-
fore, determine a solid conclusion, and should be considered
a major limitation. The low incidence of the disease also rep-
resents a limit to clinical trials.
Conclusions
Both morphological and metabolic volume can be useful
from a diagnostic and prognostic point of view in thymic
cancer and thymoma patients. The association of CT and
PET/CT images in a single step examination employing a
dedicated protocol, such as respiratory gating, could be useful
for providing complete tumor information. A large multi-
center clinical trial for confirming the findings of this study is
mandatory.
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